A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario

Hepatocellular carcinoma (HCC) is the fifth most common malignancy across the world. Alongside improvement in local approaches for early stages, the prognosis of patients with advanced disease remains poor. The tyrosine kinase inhibitor sorafenib was the first drug approved for advanced HCC. During...

Descripción completa

Detalles Bibliográficos
Autores principales: Dipasquale, Angelo, Marinello, Arianna, Santoro, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055282/
https://www.ncbi.nlm.nih.gov/pubmed/33884259
http://dx.doi.org/10.2147/JHC.S270532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055282/
https://www.ncbi.nlm.nih.gov/pubmed/33884259
http://dx.doi.org/10.2147/JHC.S270532

Ejemplares similares